Omeros Corporation Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Gross Sales: $32.2 million for Yartemlia in Q2, marking a 190% increase from Q1.

Net Sales: $28.5 million, up 188% from the previous quarter.

Net Income: Reported at $200,000 ($0.18 per share), down from $56.1 million ($0.78 per share) in Q1, influenced by non-cash adjustments.

Non-GAAP Adjusted Net Income: $1.8 million ($0.02 per share), a significant improvement from a loss of $17.1 million in Q1.

Cash and Investments: $132 million at quarter-end.

Positive Cash Flow: Generated $4.1 million from operations.

Share Repurchases: Approximately 843,000 shares repurchased at an average price of $11.70 per share.

2Strategic Updates and Business Highlights

Yartemlia Launch: The drug is positioned to become the standard of care for TA-TMA, with strong physician adoption and market penetration.

Expansion Plans: Omeros is exploring additional indications for Yartemlia and advancing its MASP-2 platform, including a long-acting MASP-2 antibody and an oral small molecule inhibitor.

Regulatory Developments: Yartemlia received a permanent J-code for reimbursement, effective July 1, and a new technology add-on payment (NTAP) from CMS, effective October 1, providing up to $287,000 in additional reimbursement for inpatient treatment.

Market Engagement: Active engagement with 175 U.S. transplant centers, with 73 unique accounts ordering Yartemlia by quarter-end.

3Forward Guidance and Outlook

Operating Expenses: Expected to increase slightly in Q3 due to higher R&D and sales/marketing expenses.

Revenue Guidance: No specific revenue guidance provided; management aims to gain more experience with prescribing trends and market dynamics.

Cash Flow: Management maintains a forecast of becoming cash flow positive company-wide by mid-2027.

4Bad News, Challenges, or Points of Concern

Regulatory Setbacks: The European Medicines Agency issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA, prompting a request for reexamination.

Market Competition: Continued off-label use of eculizumab (C5 inhibitor) remains a concern, although management believes Yartemlia's safety and efficacy will drive adoption.

Sales Variability: Management acknowledged potential month-to-month variability in sales as they navigate market dynamics.

5Notable Q&A Insights

Channel Stocking: Management confirmed that sales figures do not reflect channel stuffing; inventory levels remain consistent at about 1.5 weeks of supply.

C5 Inhibition Discussion: There is ongoing off-label use of eculizumab, but management believes Yartemlia's adoption is gaining momentum due to its safety profile.

Patient Treatment Insights: While specific patient numbers treated with Yartemlia are not disclosed, management anticipates increased diagnosis of TA-TMA as awareness and treatment options improve. Overall, Omeros reported a strong quarter with significant sales growth for Yartemlia, positive cash flow, and a commitment to expanding its product offerings despite facing regulatory challenges and competitive pressures.